SCHEMBL24257532

SCHEMBL24257532

COC(=O)C(C)(C)NC(=O)c1ncc(-c2cccc(Cl)c2)c(C)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.48
MAPK1 P28482 2/20 0.41
MAPK10 P53779 2/20 0.41
VEGFA P15692 1/20 0.41
FLT1 P17948 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
EGLN3 Q9H6Z9 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
CTSA P10619 2/20 0.40
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 1/20 0.38
ADORA1 P30542 1/20 0.38
PTGER1 P34995 5/20 0.38
CYP2C9 P11712 2/20 0.38
CYP3A4 P08684 1/20 0.38
SHMT1 P34896 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453143 1.00 CNR2 (0.48) CNR2MAPK1MAPK10VEGFAFLT1
SCHEMBL24257585 0.84 PTGER1 (0.47) MAPK1MAPK10GPR119ADORA1PTGER1
SCHEMBL30454075 0.84 PTGER1 (0.47) MAPK1MAPK10GPR119ADORA1PTGER1
SCHEMBL24257519 0.83 CNR2 (0.55) CNR2VEGFAFLT1EGLN1EGLN3
SCHEMBL24257835 0.82 VEGFA (0.49) VEGFAFLT1EGLN1EGLN3GPR119
SCHEMBL30452770 0.82 VEGFA (0.49) VEGFAFLT1EGLN1EGLN3GPR119
SCHEMBL24257584 0.80 MAPK1 (0.39) MAPK1MAPK10VEGFAFLT1EGLN1
SCHEMBL30453562 0.79 LPAR1 (0.39) MAPK1MAPK10VEGFAFLT1EGLN1
SCHEMBL24257587 0.79 LPAR1 (0.39) MAPK1MAPK10VEGFAFLT1EGLN1
SCHEMBL24257583 0.79 GABRA5 (0.41) CNR2MAPK1MAPK10VEGFAFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 CNR2 4211/4885MAPK1 255/4885MAPK10 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.